254 related articles for article (PubMed ID: 26546117)
21. Combined conjugated esterified estrogen plus methyltestosterone supplementation and risk of breast cancer in postmenopausal women.
Kabat GC; Kamensky V; Heo M; Bea JW; Hou L; Lane DS; Liu S; Qi L; Simon MS; Wactawski-Wende J; Rohan TE
Maturitas; 2014 Sep; 79(1):70-6. PubMed ID: 25011395
[TBL] [Abstract][Full Text] [Related]
22. Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort.
Lacey JV; Brinton LA; Leitzmann MF; Mouw T; Hollenbeck A; Schatzkin A; Hartge P
J Natl Cancer Inst; 2006 Oct; 98(19):1397-405. PubMed ID: 17018786
[TBL] [Abstract][Full Text] [Related]
23. Estrogen-alone therapy and invasive breast cancer incidence by dose, formulation, and route of delivery: findings from the WHI observational study.
Shufelt C; Bairey Merz CN; Pettinger MB; Choi L; Chlebowski R; Crandall CJ; Liu S; Lane D; Prentice R; Manson JE;
Menopause; 2018 Sep; 25(9):985-991. PubMed ID: 29738414
[TBL] [Abstract][Full Text] [Related]
24. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.
Rossouw JE; Anderson GL; Prentice RL; LaCroix AZ; Kooperberg C; Stefanick ML; Jackson RD; Beresford SA; Howard BV; Johnson KC; Kotchen JM; Ockene J;
JAMA; 2002 Jul; 288(3):321-33. PubMed ID: 12117397
[TBL] [Abstract][Full Text] [Related]
25. Colorectal cancer in relation to postmenopausal estrogen and estrogen plus progestin in the Women's Health Initiative clinical trial and observational study.
Prentice RL; Pettinger M; Beresford SA; Wactawski-Wende J; Hubbell FA; Stefanick ML; Chlebowski RT
Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1531-7. PubMed ID: 19423530
[TBL] [Abstract][Full Text] [Related]
26. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.
Anderson GL; Limacher M; Assaf AR; Bassford T; Beresford SA; Black H; Bonds D; Brunner R; Brzyski R; Caan B; Chlebowski R; Curb D; Gass M; Hays J; Heiss G; Hendrix S; Howard BV; Hsia J; Hubbell A; Jackson R; Johnson KC; Judd H; Kotchen JM; Kuller L; LaCroix AZ; Lane D; Langer RD; Lasser N; Lewis CE; Manson J; Margolis K; Ockene J; O'Sullivan MJ; Phillips L; Prentice RL; Ritenbaugh C; Robbins J; Rossouw JE; Sarto G; Stefanick ML; Van Horn L; Wactawski-Wende J; Wallace R; Wassertheil-Smoller S;
JAMA; 2004 Apr; 291(14):1701-12. PubMed ID: 15082697
[TBL] [Abstract][Full Text] [Related]
27. Estrogen metabolism in menopausal hormone users in the women's health initiative observational study: Does it differ between estrogen plus progestin and estrogen alone?
Falk RT; Manson JE; Barnabei VM; Anderson GL; Brinton LA; Rohan TE; Cauley JA; Chen C; Coburn SB; Pfeiffer RM; Reding KW; Sarto GE; Wentzensen N; Chlebowski RT; Xu X; Trabert B
Int J Cancer; 2019 Feb; 144(4):730-740. PubMed ID: 30183089
[TBL] [Abstract][Full Text] [Related]
28. Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status.
Munsell MF; Sprague BL; Berry DA; Chisholm G; Trentham-Dietz A
Epidemiol Rev; 2014; 36(1):114-36. PubMed ID: 24375928
[TBL] [Abstract][Full Text] [Related]
29. Postmenopausal hormone use and the risk of nephrolithiasis: results from the Women's Health Initiative hormone therapy trials.
Maalouf NM; Sato AH; Welch BJ; Howard BV; Cochrane BB; Sakhaee K; Robbins JA
Arch Intern Med; 2010 Oct; 170(18):1678-85. PubMed ID: 20937929
[TBL] [Abstract][Full Text] [Related]
30. Is the WHI relevant to HRT started in the perimenopause?
Harman SM; Brinton EA; Clarkson T; Heward CB; Hecht HS; Karas RH; Judelson DR; Naftolin F
Endocrine; 2004 Aug; 24(3):195-202. PubMed ID: 15542885
[TBL] [Abstract][Full Text] [Related]
31. Breast cancer risk with postmenopausal hormonal treatment.
Collins JA; Blake JM; Crosignani PG
Hum Reprod Update; 2005; 11(6):545-60. PubMed ID: 16150813
[TBL] [Abstract][Full Text] [Related]
32. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.
Shumaker SA; Legault C; Rapp SR; Thal L; Wallace RB; Ockene JK; Hendrix SL; Jones BN; Assaf AR; Jackson RD; Kotchen JM; Wassertheil-Smoller S; Wactawski-Wende J;
JAMA; 2003 May; 289(20):2651-62. PubMed ID: 12771112
[TBL] [Abstract][Full Text] [Related]
33. Estrogen affects post-menopausal women differently than estrogen plus progestin replacement therapy.
Tannen RL; Weiner MG; Xie D; Barnhart K
Hum Reprod; 2007 Jun; 22(6):1769-77. PubMed ID: 17347166
[TBL] [Abstract][Full Text] [Related]
34. Use of postmenopausal hormone therapies and risk of histology- and hormone receptor-defined breast cancer: results from a 15-year prospective analysis of NIH-AARP cohort.
Wang SM; Pfeiffer RM; Gierach GL; Falk RT
Breast Cancer Res; 2020 Nov; 22(1):129. PubMed ID: 33239054
[TBL] [Abstract][Full Text] [Related]
35. Ethnicity and breast cancer: factors influencing differences in incidence and outcome.
Chlebowski RT; Chen Z; Anderson GL; Rohan T; Aragaki A; Lane D; Dolan NC; Paskett ED; McTiernan A; Hubbell FA; Adams-Campbell LL; Prentice R
J Natl Cancer Inst; 2005 Mar; 97(6):439-48. PubMed ID: 15770008
[TBL] [Abstract][Full Text] [Related]
36. Menopausal hormone therapy and cancer: changing clinical observations of target site specificity.
Chlebowski RT; Anderson GL
Steroids; 2014 Nov; 90():53-9. PubMed ID: 24910928
[TBL] [Abstract][Full Text] [Related]
37. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin.
Anderson GL; Chlebowski RT; Rossouw JE; Rodabough RJ; McTiernan A; Margolis KL; Aggerwal A; David Curb J; Hendrix SL; Allan Hubbell F; Khandekar J; Lane DS; Lasser N; Lopez AM; Potter J; Ritenbaugh C
Maturitas; 2006 Sep; 55(2):103-15. PubMed ID: 16815651
[TBL] [Abstract][Full Text] [Related]
38. Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials.
Chlebowski RT; Anderson GL; Aragaki AK; Manson JE; Stefanick ML; Pan K; Barrington W; Kuller LH; Simon MS; Lane D; Johnson KC; Rohan TE; Gass MLS; Cauley JA; Paskett ED; Sattari M; Prentice RL
JAMA; 2020 Jul; 324(4):369-380. PubMed ID: 32721007
[TBL] [Abstract][Full Text] [Related]
39. Effects of postmenopausal hormone therapy on incident atrial fibrillation: the Women's Health Initiative randomized controlled trials.
Perez MV; Wang PJ; Larson JC; Virnig BA; Cochrane B; Curb JD; Klein L; Manson JE; Martin LW; Robinson J; Wassertheil-Smoller S; Stefanick ML
Circ Arrhythm Electrophysiol; 2012 Dec; 5(6):1108-16. PubMed ID: 23169946
[TBL] [Abstract][Full Text] [Related]
40. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study.
Shumaker SA; Legault C; Kuller L; Rapp SR; Thal L; Lane DS; Fillit H; Stefanick ML; Hendrix SL; Lewis CE; Masaki K; Coker LH;
JAMA; 2004 Jun; 291(24):2947-58. PubMed ID: 15213206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
